Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials

Dow Jones09-19

By Adriano Marchese

Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update, and that it was canceling its two cancer drug trial programs.

The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies.

"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions," it said.

As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents.

The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability.

The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment that uses the body's own immune system to fight certain forms of cancer. In this case, lung cancer and melanoma.

Achilles Therapeutics said that it will consider engaging third parties who are developing alternative methods to target clonal neoantigens for the treatment of cancers.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

September 19, 2024 07:44 ET (11:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468957821?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468957821","market":"fut","top_or_hot":-1,"title":"Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Achilles <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it will begin cost-cutting measures, including layoffs, as part of its strategic update,  and that it was canceling its two cancer drug trial programs. \n</p>\n<p>\n  The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies. \n</p>\n<p>\n  \"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions,\" it said. \n</p>\n<p>\n  As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents. \n</p>\n<p>\n  The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability. \n</p>\n<p>\n  The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment that uses the body's own immune system to fight certain forms of cancer. In this case, lung cancer and melanoma. \n</p>\n<p>\n  Achilles Therapeutics said that it will consider engaging third parties who are developing alternative methods to target clonal neoantigens for the treatment of cancers. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 19, 2024 07:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update,  and that it was canceling its two cancer drug trial ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2468957821","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468957821","pubTimestamp":1726746240,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update,  and that it was canceling its two cancer drug trial programs.The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies.\"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions,\" it said.As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents.The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability.The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment tha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","ACHL":"Achilles Therapeutics plc"},"translate_title":"Achilles Therapeutics将裁员作为审查的一部分，并停止药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHL":1,"LENZ":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update,  and that it was canceling its two cancer drug trial programs. \n\n\n  The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies. \n\n\n  \"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions,\" it said. \n\n\n  As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents. \n\n\n  The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability. \n\n\n  The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment that uses the body's own immune system to fight certain forms of cancer. In this case, lung cancer and melanoma. \n\n\n  Achilles Therapeutics said that it will consider engaging third parties who are developing alternative methods to target clonal neoantigens for the treatment of cancers. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 19, 2024 07:44 ET (11:44 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468957821"}